On July 29, 2016 Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, reported that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for its lead program, NEO-PV-01 (Press release, Neon Therapeutics, JUL 29, 2016, View Source [SID:1234514147]). NEO-PV-01 is a personalized vaccine designed specifically for each patient based on the neoantigen mutations unique to that patient’s tumor DNA. Schedule your 30 min Free 1stOncology Demo! The IND enables Neon Therapeutics to initiate its first clinical study, which is a multicenter Phase 1b clinical trial evaluating the safety, tolerability and efficacy of NEO-PV-01 with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor from Bristol-Myers Squibb, in melanoma, non-small cell lung cancer and bladder cancer. The trial will evaluate immune responses in serial samples of peripheral blood and tumor tissue through a comprehensive immune monitoring program.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are in the midst of tremendous momentum for neoantigen biology in the field of cancer immunotherapy," said Cary Pfeffer, M.D., interim chief executive officer of Neon Therapeutics. "This IND filing acceptance brings us one step closer to deliver on the promise of neoantigen science to bring truly personalized cancer therapies to patients living with this devastating disease."
This clinical trial is expected to begin in 2016, and is anticipated to enroll a total of 90 patients from multiple clinical sites in the U.S. More information about the trial will be available at www.clinicaltrials.gov.